Related Experiment Videos
ACE inhibitors before or after heart failure?
1Section of Cardiology, Malmö University Hospital, Sweden.
Insights
Early intervention with angiotensin-converting enzyme (ACE) inhibitors can improve outcomes for individuals at high risk of heart failure. Identifying these patients before symptoms appear is crucial for preventive treatment strategies.
Area of Science:
- Cardiology
- Preventive Medicine
Background:
- Heart failure is a progressive condition with deteriorating cardiac function or sudden death.
- Cardiac changes and left ventricular remodeling occur before clinical symptoms manifest.
- Compensatory cardiac adaptations can indicate increased risk for heart failure and cardiac events.
Purpose of the Study:
- To identify individuals at high risk for heart failure before symptom onset.
- To explore the benefits of preventive treatment with angiotensin-converting enzyme (ACE) inhibitors.
- To investigate objective methods for characterizing left ventricular state in at-risk patients.
Main Methods:
- Assessing left ventricular dimensions, volume, mass, and systolic function as prognostic markers.
- Evaluating the impact of early angiotensin-converting enzyme (ACE) inhibitor treatment.
- Developing strategies for identifying asymptomatic individuals with impaired left ventricular function.
Main Results:
- Increased left ventricular dimensions, volume, mass, and reduced systolic function are markers of poor prognosis.
- Angiotensin-converting enzyme (ACE) inhibitors improve prognosis when administered before clinical heart failure onset.
- Objective characterization of the left ventricle is necessary for risk identification.
Conclusions:
- Early identification of at-risk individuals using objective left ventricular assessments is critical.
- Preventive treatment with angiotensin-converting enzyme (ACE) inhibitors may reduce new-onset clinical heart failure.
- Patients with impaired left ventricular dysfunction, not just reduced systolic function, may benefit from ACE inhibitors.
Abstract:
Heart failure is a progressive disease and once the process has started it continues with further deterioration of cardiac function or ends in sudden death. In many patients changes within the heart start to develop long before clinical symptoms occur. The left ventricle goes through a number of adaptions-remodelling-to compensate for increased pressure or volume load or subsequent myocardial infarction. Several of these compensatory changes have prognostic implications and indicate increased risk of clinical heart failure or cardiac events. Thus, increased left ventricular dimensions, volume and mass together with reduced systolic function are all markers of poor prognosis. Treatment with angiotensin-converting enzyme (ACE) inhibitors before the onset of clinical heart failure has been shown to improve prognosis. Identification of individuals at high risk is difficult since signs and symptoms of heart failure are often lacking. A strategy to find these patients must use objective methods to characterise the state of the left ventricle. It is likely that not only patients with significant reduction of systolic function but also other signs of impaired left ventricular dysfunction will benefit from treatment with ACE inhibitors. Only by preventive treatment may we be able to decrease the number of patients with new onset of clinical heart failure.